Skip to main content

Table 2 Comparison between PsA patients and controls at baseline

From: Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up

  Patients
N = 39
Controls
N = 39
p-value
Women, n(%) 25 (64.1) 29 (74.4) 0.462
Men, n(%) 14 (35.9) 10 (25.6)  
Age years 55 (48–62) 56 (48–60) 0.617
Body weight kg 106.0 (93.5–112.5 107.0 (96.5–122.2) 0.358
Body height cm 168.0 (161.0–176.0) 165.0 (161.0–170.0) 0.180
BMI kg/m2 35.2 (33.9–37.9) 38.5 (36.9–41.7) < 0.001
Waistline cm 115.0 (112.0–122.0) 117.0 (107–126.5) 0.635
BP systolic mmHg 127.5 (115.0–136.0) 122.0 (115.0–137.0) 0.503
BP diastol mmHg 77.5 (70.0–82.5) 77.0 (70.0–85.0) 0.736
CRP mg/L 5 (3–9) 4 (2–6) 0.137
Hb g/L 144 (131–150) 141 (135–149) 0.881
WBC 109/L 6.1 (5.3–7.7) 6.6 (5.6–7.6) 0.719
PLT 109/L 270 (202–299) 266 (225–302) 0.924
S-TC mmol/L 5.5 (4.6–6.2) 4.9 (4.1–5.6) 0.034
S-LDL mmol/L 3.6 (3.0–4.4) 3.2 (2.54.0) 0.08
S- HDL mmol/L 1.4 (1.1–1.6) 1.4 (1.0–1.6) 0.867
S- TG mmol/L 1.6 (1.2–2.4) 1.7 (1.2–2.1) 0.512
HbA1c mmol/mol 35.5 (32.0–37.2) 37.5 (35.0–44.0) 0.003
S-glucose mmol/L 5.7 (5.3–6.2) 6.2 (5.8–7.1) 0.003
Creatinine μmol/L 75 (64–84) 68 (62–79) 0.240
S-urate μmol/L 330 (280–400) 350 (283–384) 0.928
ALT μkat/L 0.52 (0.41–0.68) 0.50 (0.42–0.68) 0.806
Anti-hypertensives, n (%) 17 (43.6) 16 (41.0) 0.819
Lipid lowering therapy n (%) 6 (15.4) 11 (28.2) 0.170
Oral anti-diabetics n (%) 1 (2.6) 4 (10.3) 0.358
Insulin n (%) 0 (0) 1 (2.6) 1.00
Allopurinol, n (%) 2 (5.1) 1 (2.6) 1.00
Mets n (%) 30 (76.9) 28 (71.8) 0.614
  1. ALT = alanine transaminase, BMI = Body Mass Index, BP = blood pressure, CRP = C- reactive protein, Hb = hemoglobin HbA1c = glycosylated hemoglobin, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, PLT = platelet count, S– =serum, TC = total cholesterol, TG = triglycerides, Mets = metabolic syndrome, WBC = White Blood Cell count